Kato H
Department of Obstetrics and Gynecology, Yamaguchi University School of Medicine.
Nihon Rinsho. 1996 Jun;54(6):1637-41.
Clinical Value of tumor markers in gynecologic malignancies is discussed with regard to their possible role in the future. Generally, the first choices of tumor markers include SCC antigen for squamous cell carcinoma and CA125 for adenocarcinoma and uterine sarcoma. Also, recent data regarding the biological function of some tumor markers, e.g., inhibition of cysteine protease by SCC antigen, have provided new information for understanding the malignant behavior of tumor cells, which would be useful for setting up new diagnostic and therapeutic modalities against malignant tumor in the future.
本文讨论了肿瘤标志物在妇科恶性肿瘤中的临床价值及其在未来可能发挥的作用。一般来说，肿瘤标志物的首选包括用于鳞状细胞癌的鳞状细胞癌抗原（SCC抗原）以及用于腺癌和子宫肉瘤的CA125。此外，关于某些肿瘤标志物生物学功能的最新数据，例如SCC抗原对半胱氨酸蛋白酶的抑制作用，为理解肿瘤细胞的恶性行为提供了新信息，这将有助于未来建立针对恶性肿瘤的新诊断和治疗模式。
